Welcome to Scrip
Create an account to read this article
Already a subscriber?
Bayer Schering Pharma and Chinese Anti-Cancer Association recently kicked off the "dandelion program", which aims to promote the widespread adoption of the consensus on bone metastasis in malignant tumor and bone-related diseases diagnosis. The program will bring international updates of standardized treatment concepts to 2,000 clinical physicians to enrich their clinical experience in cancer treatment such as palliative treatment skills for active cancer symptoms and pain relief. At the same time, it will strengthen the capability of tumor patients and their relatives to identify false medical information and to understand relevant anti-cancer knowledge. (Click here for more - Chinese language)
Create an account to read this article
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
After “intense negotiations”, Bavarian Nordic’s board plans to recommend a DKK19bn ($2.98bn) offer by private equity firms Nordic Capital and Permira to take the company private.
Dr Reddy’s CEO discusses the growth opportunity for semaglutide, including production capacity and ‘crazy’ demand indications, and a potential 20-plus product GLP-1 portfolio. All eyes are also on an upcoming hearing in India pertaining to Novo Nordisk’s semaglutide patent in the country.
Deal Snapshot: The addition of Hengrui's HRS-9821, a China-originated fast-follower of Verona’s Ohtuvayre in chronic obstructive pulmonary disease, should enable GSK’s COPD therapy portfolio to stack up well against increasing competitors in the indication, including biologics and small molecules.